by Doug Feekin | Jul 28, 2021 | Medicare Advantage, Medicare Supplement, news
Humana reported 2nd quarter 2021 Medicare Supplement lives of 330,400, a 0.7% increase over 1st quarter 2021 and a 1.8% increase over 2nd quarter 2020. The table below shows Humana’s Medicare Supplement enrollment counts by quarter since 1st quarter 2017. Humana...
by Carrie Haubensak | Jul 22, 2021 | Medicare Advantage, Medicare Supplement, news
2nd Quarter 2021 Highlights: Operating Revenue: Operating revenue was $33.3 billion in the second quarter of 2021, an increase of $4.1 billion, or 14.1 percent, versus the prior year quarter and 15.8 percent after adjusting for the repeal of the health insurance tax...
by Jason Yoo | Jul 16, 2021 | Medicare Advantage, Medicare Supplement, news
2nd Quarter 2021 Highlights: Revenues of $71.3 Billion Grew 15% Earnings from Operations were $6.0 Billion The second quarter 2021 medical care ratio of 82.8% compared to 70.2% last year, with the variance due to second quarter 2020 COVID-19 effects Based upon first...
by Carrie Haubensak | Jun 29, 2021 | Competitive Intelligence, Insurance Industry, Medicare Supplement, news
CompanyEffective DateAverage IncreaseComments Accendo Insurance Company 7/1/20213.0%Missouri Aetna Health and Life Insurance Company 8/1/20215.7%Arkansas Aetna Health Insurance Company 8/1/20215.3%Colorado American Continental Insurance Company (Aetna)...
by Jason Yoo | Jun 24, 2021 | Medicare Supplement, Uncategorized
A correction has been posted to the Plan F Premium Rate Scorecard published posted on June 4, 2021. The CSG Actuarial Premium Rate Scorecard™ provides an overall premium rate competitiveness ranking by company across all states, plans, ages, genders, households, and...
by Jason Yoo | Jun 17, 2021 | Medicare Advantage, Medicare Supplement, news
Overview The United States Food and Drug Administration (FDA) recently announced accelerated approval of a new Alzheimer’s disease treatment developed by Biogen called ADUHELM. This approval is significant in many ways. Aduhelm is the first novel therapy approved for...
